TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
399
Frequently Asked Questions
What is Market Cap of TG Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. TG Therapeutics Inc market cap is $6.08B.
What is the 52-week high for TG Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. TG Therapeutics Inc 52 week high is $44.65 as of May 27, 2026.
What is the 52-week low for TG Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. TG Therapeutics Inc 52 week low is $25.28 as of May 27, 2026.
What is TG Therapeutics Inc stock price today?
TG Therapeutics Inc stock price today is $39.94.
What was TG Therapeutics Inc stock price yesterday?
TG Therapeutics Inc stock price yesterday was $39.73.
What is the PE ratio of TG Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. TG Therapeutics Inc's P/E ratio is 13.85.
What is the Price-to-Book ratio of TG Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. TG Therapeutics Inc P/B ratio is 10.4306.
What is the 50-day moving average of TG Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. TG Therapeutics Inc 50-day moving average is $35.64.